PITTSBURGH, Aug. 14 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Venlafaxine Hydrochloride Tablets 25 mg (base), 37.5 mg (base), 50 mg (base), 75 mg (base) and 100 mg (base).

Venlafaxine HCl Tablets are indicated for the treatment of major depressive disorder. They are the AB-rated generic version of Wyeth's Effexor^® Tablets, which had annual U.S. sales of approximately $154 million for the 12 months ending June 30, 2006.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit www.mylan.com.

SOURCE Mylan Laboratories Inc.
08/14/2006

CONTACT: Patrick Fitzgerald, +1-724-514-1800, or Kris King,
+1-724-514-1800, both of Mylan Laboratories Inc.
Web site: http://www.mylan.com
(MYL)